| 抗新型冠状病毒单克隆中和抗体药物研发进展* |
| |
| 引用本文： | 史瑞,严景华.抗新型冠状病毒单克隆中和抗体药物研发进展*[J].中国生物工程杂志,2021,41(6):129-135. |
| |
| 作者姓名： | 史瑞 严景华 |
| |
| 作者单位： | 中国科学院微生物研究所 北京 100101 |
| |
| 基金项目： | * 国家重点研发计划(2020YFC0848300) |
| |
| 摘 要： | 随着新型冠状病毒肺炎(COVID-19)疫情在全球的不断蔓延,开发有效的治疗药物迫在眉睫。中和抗体作为最有希望的新型冠状病毒特异性治疗药物,已经在临床研究中展现很好的治疗效果。对抗新冠病毒单克隆中和抗体药物研发的进展、涉及的主要技术和主要临床试验结果进行了总结,以期为包括COVID-19在内的新发、突发传染病中和抗体药物研发提供参考。
|
| 关 键 词： | 新型冠状病毒 中和抗体药物 临床试验 |
| 收稿时间： | 2021-05-14 |
Research Progress of Neutralizing Antibody Drugs against SARS-CoV-2 |
| |
| SHI Rui,YAN Jing-hua.Research Progress of Neutralizing Antibody Drugs against SARS-CoV-2[J].China Biotechnology,2021,41(6):129-135. |
| |
| Authors: | SHI Rui YAN Jing-hua |
| |
| Abstract: | With the continuous spread of the COVID-19 epidemic, it is urgent to develop effective therapeutic drugs. Neutralizing antibodies, as the most promising specific therapeutics against SARS-CoV-2, are proved to be effective in clinical trials. The research progress of neutralizing antibodies were summarized, including the involved technologies, and the clinical results in order to provide benefits for developing neutralizing antibodies in emerging infectious diseases including COVID-19. |
| |
| Keywords: | SARS-CoV-2 Neutralizing antibodies Clinical trial |
|
| 点击此处可从《中国生物工程杂志》浏览原始摘要信息 |
| 点击此处可从《中国生物工程杂志》下载免费的PDF全文 |
